Edward Agyare, Ph.D.

Division Director and Associate Professor Pharmaceutical Sciences
LOCATION: Tallahassee, Dyson Room 228
EMAIL: edward.agyare@famu.edu
PHONE: 850-599-3581


Edward Agyare, Ph.D., serves as the associate professor, Basic Pharmaceutical Sciences, and as the division director of Pharmaceutical Sciences.
Dr. Agyare’s laboratory works with a variety of nanoparticles for imaging and chemotherapy. He has previously loaded Magnevist®, a contrast agent, into liposomal nanoparticle for magnetic resonance imaging (MRI) of pancreatic cancer in vivo and performed the first comprehensive biodistribution and pharmacokinetic analysis of such a nanoprobe. He has also developed techniques to enhance the signal-to-noise ratio of tumor-imaging using such nanoprobes. Dr. Agyare’s previous work with drug delivery system has focused extensively on using gemcitabine loaded-thermosensitive liposomal nanoparticle-mediated hyperthermia to sensitize tumors to gemcitabine and defined a novel dual mechanism of action involving anti-hypoxic and vascular disrupting properties of this approach. In anticipation of clinical translation of this paradigm, his laboratory is currently developing a theranostic nanoparticle that combines Magnevist® and modified gemcitabine as one unit that would have the ability to detect and suppress pancreatic tumor growth. He has successfully collaborated with leading investigators in his area of research and produced several peer-reviewed publications.
With his research career of 6 years, Dr. Agyare has trained and graduated 2 Ph.D. students who are gainfully employed. Currently, he is expertly training 3 Ph.D. students and one postdoctoral fellow in his lab.

    • Postdoctoral Fellow: The University of Texas, MD Anderson Cancer Center, Houston, Texas.
    • Visiting Fellow: Mayor Clinic Graduate School, Rochester, MN.
    • Visiting Scientist: The University of Texas, MD Anderson Cancer Center, Houston, Texas
Areas of Expertise
    • Drug Delivery
    • Tumor Targeting
    • Biodiversity
    • Nanotechnology and Nanomedicine
Research Interest
  • Development of theranostics for the early diagnosis and treatment of pancreatic cancer.

  • Mechanisms of nanotechnology-based modified anticancer drug delivery, with emphasis on understanding how various biological barriers influence the effectiveness of delivery systems.

Selective Publications
  • Smith, T. Affram, K. Bulumko, E. Agyare, E. (2018) Evaluation of in-vitro cytotoxic effect of 5-FU loaded-chitosan nanoparticles against spheroid models. J Nat Sci., 4(10). PMCID: PMC 6364702

  • Scarton L, Yoon S, Oh S, Agyare E, Trevino J, Han B, Lee E, Setiawan VW, Permuth JB, Schmittgen TD, Odedina FG, Wilkie DJ (2018). Pancreatic Cancer Related Health Disparities: A Commentary. Cancers (Basel) 10(235) PMCID: PMC 6070801

  • Kevin Affram, Udofot Ofonime, Renee Reams, Sunil. Krishnan, Mandip. Sachdeva, Jens Rosenberg, Edward Agyare (2017). Smart thermosensitive liposomes for effective solid tumor therapy and in vivo imaging. PLoS ONE: 12(9):e0185116. PMCID: PMC5608370

  • Udofot, O., Affram K., T. Smith, B. Tshabe, S. Krishnan, M. Sachdeva, E. Agyare (2016). Pharmacokinetics, biodistribution, and therapeutic efficacy of 5-fluorouracil-loaded pH-sensitive PEGylated liposomal nanoparticles in HCT-116 tumor bearing mouse. Journal of Nature and Science (JNSCI), 2(1):e171: PMCID: PMC4869888

  • Kevin Affram, Ofonime Udofot, Edward K. Agyare. Cytotoxicity of gemcitabine-loaded thermosensitive liposomes in pancreatic cancer cell lines. Integr Cancer Sci Therapy, 2015. 2(2): 133-142 PMID: 26090123, PMCID:PMC4469203